Skip to main content Accessibility help
×
Home
Hostname: page-component-747cfc64b6-nvdzj Total loading time: 0.3 Render date: 2021-06-14T06:46:57.516Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true }

Correspondence

Published online by Cambridge University Press:  12 March 2007

JOHN F. ALOIA
Affiliation:
Bone Mineral Research Center, Winthrop University Hospital, Mineola, NY 11501, USA
MELISSA LI-NG
Affiliation:
Bone Mineral Research Center, Winthrop University Hospital, Mineola, NY 11501, USA
Corresponding
E-mail address:
Rights & Permissions[Opens in a new window]

Abstract

Type
Correspondence
Copyright
Copyright © Cambridge University Press 2007

To The Editor:

The occurrence of the common cold and influenza shows clear seasonality. The cold and influenza season corresponds to the season of vitamin D insufficiency. This association was highlighted in the recent article in this journal by Cannell et al. [Reference Cannell1], which proposed that the lack of vitamin D during the winter may be a ‘seasonal stimulus’ to the infectivity of the influenza virus.

Vitamin D is produced in the skin when sunlight is absorbed. Thus, vitamin D levels, or serum 25-hydroxyvitamin D (25-OHD), fluctuate seasonally. At latitudes above 37° N and below 37° S, sunlight is insufficient to induce cutaneous vitamin D synthesis during the winter months so 25-OHD levels are low [Reference Webb, Kline and Holick2]. New evidence has accumulated that vitamin D can have important functions in the immune system, specifically the innate immune system. Is our susceptibility to colds and influenza related to vitamin D insufficiency in the wintertime? Furthermore, would vitamin D supplementation boost our immune system and work as a preventive measure for colds and influenza?

We considered these questions after reviewing the adverse events of a vitamin D3 supplementation trial that we completed [Reference Aloia3]. The design and primary results of the study have been published and are summarized here. We conducted a 3-year randomized controlled trial to test the hypothesis that vitamin D3 supplementation would prevent bone loss in calcium-replete, African-American post-menopausal women. A total of 208 women were randomized to receive vitamin D3 (n=104) or placebo (n=104). After 2 years, the vitamin D3 dose was increased to 50 μg/d (2000 IU) in the active group. None of the patients had a history of chronic obstructive pulmonary disease, congestive heart failure, or myocardial infarction. Few patients had a history of asthma and seasonal allergies with no significant difference between the vitamin D3 group and the placebo group.

The study was approved by the Institutional Review Board of Winthrop University Hospital. After randomization, patients were followed up every 6 months for 3 years. At each visit, information on URI symptoms was obtained by first asking the participants, ‘Have you been well?’ If the participant answered ‘No’, then she was asked, ‘Have you had any colds or influenza?’ A report of cold and influenza was recorded as an adverse event.

After 3 years, a total of 34 patients reported cold and influenza symptoms, eight in the vitamin D3 group vs. 26 in the placebo group (P<0·002). When we examined the seasonality of the symptoms, we found that the placebo group had cold/influenza symptoms mostly in the winter. The vitamin D group had symptoms throughout the year while on 20 μg/d, whereas only one subject had a cold/influenza while on 50 μg/d (Fig.). None of the 34 patients with reported cold and influenza symptoms had significant comorbidities.

Fig. Incidence of reported cold/influenza symptoms according to season. The placebo group reported more cold/influenza symptoms in the winter. Only one subject had cold/influenza symptoms while taking high doses of vitamin D (50 μg/d). ■, Placebo; , 20 μg/d vitamin D; □, 50 μg/d vitamin D.

Vitamin D supplementation, particularly at higher doses, may protect against the ‘typical’ winter cold and influenza. A major flaw in this analysis is that the data on viral URI symptoms were collected in an insensitive and imprecise way. From a 3-year trial on 208 subjects, we would expect at least 139 colds, but we only collected 39 reports of viral URI symptoms, indicating the incomplete capture of data. However, given the double-blinded, randomized nature of this trial, the responses should not have been biased.

The physiological basis of the protective effect of vitamin D lies in its ability to stimulate innate immunity and to moderate inflammation. The active form of vitamin D, 1,25-dihydroxyvitamin D (1,25-OH2D) stimulates the genetic expression of antimicrobial peptides (AMPs) in human monocytes, neutrophils, and epithelial cells [Reference Wang4]. Recognition of microbial particles by toll-like receptors (TLRs) induces expression of antimicrobial peptides, such as defensins and cathelicidins. These peptides have a broad range of actions against microorganisms, including bacteria, fungi and viruses. Liu et al. showed that stimulation of TLR 2/1 engages a vitamin D-dependent intracellular circuit that results in the expression of cathelicidin, enhancing the microbicidal capability of the monocyte [Reference Liu5]. Remarkably, the authors also observed that sera from African-American individuals, who are known to have substantially lower serum vitamin D levels than whites, were inefficient in inducing genetic expression of cathelicidin. When the authors supplemented the sera with 25-OHD, cathelicidin levels increased to levels observed in monocytes collected from whites. Wang et al. showed that 1,25-OH2D induces expression of cathelicidin and defensin β2 genes [Reference Wang4]. Defensin β2 has been shown to have inhibitory effects on adenovirus and HIV-1 [Reference Bastian and Schafer6, Reference Sun7]. Defensins can block viral infection by directly acting on the virion or by affecting the target cell and thereby indirectly interfering with viral infection [Reference Kotman and Chang8]. One of the defensins called retrocyclin-2 inhibits influenza virus infection by blocking membrane fusion mediated by the viral hemagglutinin [Reference Leikina9].

These reports provide a rationale for vitamin D supplementation in the prevention of colds and influenza. Since there is an epidemic of vitamin D insufficiency in the United States, the public health impact of this observation could be great. These findings should be confirmed by randomized, placebo-controlled trials.

Declaration of Interest

This research was supported by the National Institutes of Aging (RO1 AG15325), National Institutes of Health, Bethesda, MD.

The authors reply:

We are obviously pleased with Drs Aloia and Li-Ng's post-hoc analysis, which found that supplemental cholecalciferol reduced the self-reported incidence of colds and influenza. Their work supports our theory that the seasonality of influenza is caused by the seasonality of 25-hydroxy-vitamin D [25(OH)D] levels [Reference Cannell1] and that vitamin D is Hope-Simpson's long-lost ‘seasonal stimulus’ [Reference Hope-Simpson2]. They lend crucial support to Hope-Simpson's 1992 prediction that ‘understanding the mechanism of action (of the seasonal stimulus) may be of critical value in designing prophylaxis against the disease’ [2, p. 235].

Aloia and Li-Ng found that the self-reported symptoms of colds and influenza were more than three times higher in the placebo group (30/104 patients) than in the vitamin D group (9/104 patients) over the entire 3 years of their study. We were somewhat surprised by such a robust effect, especially with the relatively low dose of 20 μg (800 IU)/d used during the first 2 years of their study.

As they point out, the next – and vitally important – step is a controlled interventional trial. In spite of the apparent effectiveness of 20 μg of cholecalciferol, and the more robust effect of 50 μg (2000 IU), we believe that trial should use enough cholecalciferol to raise 25(OH)D levels to those achieved by natural summertime sun exposure, about 50 ng/ml. At the end of the final year of their original trial, 50 μg/d still left many African-American women vitamin D-deficient; about 40% had 25(OH)D levels less than 32 ng/ml.

Furthermore, such a trial should use cholecalciferol, not ergocalciferol. Ergocalciferol is not vitamin D but a less potent vitamin D analogue that plays no role in normal human physiology [Reference Houghton and Vieth3]. Measuring 25(OH)D levels at baseline and periodically thereafter would assess compliance, the effect of the intervention, and avoid confounding factors which might otherwise go undetected. Serological tests done on baseline and convalescent serum could be used to confirm viral respiratory infections.

The lack of seasonality in their vitamin D group compared to their placebo group is intriguing. The vitamin D group reported a lower incidence of respiratory infections, but when they did get sick, they were just as likely to get sick in the summer as the winter. That is, the vitamin D abolished the seasonality of colds and influenza. We hypothesize their subjects continued to suffer rhinovirus infections.

Noah found that rhinovirus infections, which cause about 50% of common colds, have no significant seasonality [Reference Noah4]. Furthermore, the seasonality of the common cold [Reference Frost and Grover5] is quite different from the seasonality of epidemic influenza. Unlike epidemic influenza, common colds do not disappear during the summer, although the incidence is less in the warmer months.

Rhinoviruses are not enveloped with a lipoprotein coat and thus may be resistant to the mechanism of action of most antimicrobial peptides (AMPs) [Reference Zhang, Ross and Blecha6]. Although, to our knowledge, AMPs have not been shown to inactivate rhinoviruses, Duits et al. found AMPs may orchestrate a secondary innate immune response to the virus [Reference Duits7]. As such, we hypothesize that vitamin D will not prevent rhinovirus infections but it may attenuate their course.

Noah did find that influenza A and B, parainfluenza 1 and 2, and respiratory syncytial viruses are all more common in the winter. As all are enveloped viruses, they all may be sensitive to AMPs and potential targets of vitamin D. It is also intriguing that HIV, which is also enveloped, is inhibited by AMPs; there is evidence that vitamin D plays a role in HIV [Reference Villamor8]. Invasive pneumococcal disease [Reference Dowell9], meningococcal disease [Reference Jensen10] and group A streptococcal disease [Reference Vlaminckx11] are highly seasonal and are sensitive to AMPs [Reference Lee12Reference Ryan14].

Drs Aloia and Li-Ng's work make it reasonable to believe that physiological doses of vitamin D prevent many viral respiratory infections. Furthermore, the dramatically increased production of AMPs by vitamin D and the broad spectrum of action of AMPs make it reasonable to hypothesize that other seasonal infections may be prevented as well. Using the same logic, it is also reasonable to postulate that pharmacological doses of vitamin D may be effective adjuvants in a breathtakingly large number of life-threatening infections.

Declaration of Interest

Dr Cannell heads the non-profit educational group, ‘The Vitamin D Council’.

References

Cannell, JJ, et al. Epidemic influenza and vitamin D. Epidemiology and Infection 2006; 134: 11291140.CrossRefGoogle ScholarPubMed
Webb, AT, Kline, L, Holick, MF. Influence of season and latitude on the cutaneous synthesis of vitamin D; exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. Journal of Clinical Endocrinology and Metabolism 1988; 67: 373378.CrossRefGoogle Scholar
Aloia, JF, et al. A randomized controlled trial of vitamin D3 supplementation in African American women. Archives of Internal Medicine 2005; 165: 16181623.CrossRefGoogle ScholarPubMed
Wang, T, et al. 1,25-Dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. Journal of Immunology 2004; 173: 29092912.CrossRefGoogle ScholarPubMed
Liu, PT, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 17701773.CrossRefGoogle ScholarPubMed
Bastian, A, Schafer, H. Human α-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regulatory Peptides 2001; 103: 15161521.Google Scholar
Sun, L, et al. Human β-defensins suppress human immunodeficiency virus infection: potential role in mucosal protection. Journal of Virology 2005; 79: 1431814329.CrossRefGoogle ScholarPubMed
Kotman, ME, Chang, TL. Defensins in innate antiviral immunity. Immunology 2006; 6: 447456.Google Scholar
Leikina, E, et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nature Immunology 2005; 6: 9951001.CrossRefGoogle Scholar
You have Access
141
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Correspondence
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Correspondence
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Correspondence
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *